A L L Rocha1, L C Faria2, T C M Guimarães2, G V Moreira1, A L Cândido2, C A Couto2, F M Reis3,4. 1. Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 2. Department of Internal Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 3. Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. fmreis@ufmg.br. 4. Division of Human Reproduction, Departments of Obstetrics and Gynecology, Hospital das Clínicas, Universidade Federal de Minas Gerais, Av. Alfredo Balena, 110, 9˚ andar, Belo Horizonte, MG, 30130-100, Brazil. fmreis@ufmg.br.
Abstract
PURPOSE: Non-alcoholic fatty liver disease (NAFLD) is an insidious pathologic condition that can manifest from simple steatosis to steatohepatitis (NASH) with potential progression to cirrhosis. Like the polycystic ovary syndrome (PCOS), NAFLD is associated with obesity, diabetes mellitus, insulin resistance and metabolic syndrome. PCOS women have an increased risk of NAFLD, but it is debatable which features of PCOS, either specific (androgen excess) or unspecific (metabolic derangements) affect the NAFLD risk. METHODS: We performed a systematic review and meta-analysis of studies that addressed the association of PCOS and NAFLD. We selected 17 studies published between 2007 and 2017 that included 2734 PCOS patients and 2561 controls of similar age and body mass index (BMI). RESULTS: PCOS patients have increased prevalence of NAFLD (odds ratio 2.54, 95% confidence interval 2.19-2.95). PCOS women with hyperandrogenism (classic phenotype) have a higher prevalence of NAFLD compared to women with PCOS without hyperandrogenism, even after correction for confounding variables. Among women with PCOS, those with NAFLD have higher serum total testosterone (mean difference 0.40 nmol/L, 95% CI 0.29-0.50 nmol/L) and free androgen index (mean difference 4.46, 95% CI 3.53-5.39) than those without NAFLD. The studies that used multivariate analysis controlling for age, BMI, triglycerides, and insulin resistance index confirmed that serum androgens are independent predictors of NAFLD in women with PCOS. CONCLUSION: The prevalence of NAFLD is increased in women with PCOS and the presence of NAFLD is associated with high serum androgen levels, in addition to obesity and insulin resistance.
PURPOSE:Non-alcoholic fatty liver disease (NAFLD) is an insidious pathologic condition that can manifest from simple steatosis to steatohepatitis (NASH) with potential progression to cirrhosis. Like the polycystic ovary syndrome (PCOS), NAFLD is associated with obesity, diabetes mellitus, insulin resistance and metabolic syndrome. PCOSwomen have an increased risk of NAFLD, but it is debatable which features of PCOS, either specific (androgen excess) or unspecific (metabolic derangements) affect the NAFLD risk. METHODS: We performed a systematic review and meta-analysis of studies that addressed the association of PCOS and NAFLD. We selected 17 studies published between 2007 and 2017 that included 2734 PCOSpatients and 2561 controls of similar age and body mass index (BMI). RESULTS:PCOSpatients have increased prevalence of NAFLD (odds ratio 2.54, 95% confidence interval 2.19-2.95). PCOSwomen with hyperandrogenism (classic phenotype) have a higher prevalence of NAFLD compared to women with PCOS without hyperandrogenism, even after correction for confounding variables. Among women with PCOS, those with NAFLD have higher serum total testosterone (mean difference 0.40 nmol/L, 95% CI 0.29-0.50 nmol/L) and free androgen index (mean difference 4.46, 95% CI 3.53-5.39) than those without NAFLD. The studies that used multivariate analysis controlling for age, BMI, triglycerides, and insulin resistance index confirmed that serum androgens are independent predictors of NAFLD in women with PCOS. CONCLUSION: The prevalence of NAFLD is increased in women with PCOS and the presence of NAFLD is associated with high serum androgen levels, in addition to obesity and insulin resistance.
Authors: F Angelico; M Del Ben; R Conti; S Francioso; K Feole; S Fiorello; M G Cavallo; B Zalunardo; F Lirussi; C Alessandri; F Violi Journal: J Clin Endocrinol Metab Date: 2004-12-14 Impact factor: 5.958
Authors: J J Kim; D Kim; J Y Yim; J H Kang; K H Han; S M Kim; K R Hwang; S Y Ku; C S Suh; S H Kim; Y M Choi Journal: Aliment Pharmacol Ther Date: 2017-03-30 Impact factor: 8.171
Authors: Maya Gambarin-Gelwan; Sanjiv V Kinkhabwala; Thomas D Schiano; Carol Bodian; Hsu-Chong Yeh; Walter Futterweit Journal: Clin Gastroenterol Hepatol Date: 2007-02-06 Impact factor: 11.382
Authors: M G Radaelli; F Martucci; S Perra; S Accornero; G Castoldi; G Lattuada; G Manzoni; G Perseghin Journal: J Endocrinol Invest Date: 2017-11-30 Impact factor: 4.256
Authors: Chelsea W Fox; Lingzhi Zhang; Abhishek Sohni; Manuel Doblado; Miles F Wilkinson; R Jeffrey Chang; Antoni J Duleba Journal: Endocrinology Date: 2019-12-01 Impact factor: 4.736
Authors: Viktor V Smirnov; Narasimha M Beeraka; Dmitry Yu Butko; Vladimir N Nikolenko; Sergey A Bondarev; Evgeniy E Achkasov; Mikhail Y Sinelnikov; P R Hemanth Vikram Journal: Reprod Sci Date: 2022-06-28 Impact factor: 2.924
Authors: Balachandran Kumarendran; Michael W O'Reilly; Konstantinos N Manolopoulos; Konstantinos A Toulis; Krishna M Gokhale; Alice J Sitch; Chandrika N Wijeyaratne; Arri Coomarasamy; Wiebke Arlt; Krishnarajah Nirantharakumar Journal: PLoS Med Date: 2018-03-28 Impact factor: 11.069
Authors: Semanti Chakraborty; Mohd Ashraf Ganie; Ibrahim Masoodi; Manisha Jana; Nandita Gupta; Nighat Yaseen Sofi Journal: Indian J Med Res Date: 2020-04 Impact factor: 2.375